Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | RARB | P10826 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22238893 | 1.00 | TP53 (0.66) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL28461372 | 1.00 | TP53 (0.66) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL29044815 | 1.00 | TP53 (0.66) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL557530 | 1.00 | TP53 (0.66) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL557505 | 1.00 | TP53 (0.66) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL28258061 | 0.88 | ALDH1A1 (0.65) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL14097198 | 0.88 | TP53 (0.82) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL7911508 | 0.88 | TP53 (0.82) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL209561 | 0.88 | TP53 (0.82) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 | |
| SCHEMBL2181009 | 0.88 | TP53 (0.82) | TP53TSHRPLA2G4BALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239785-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | claimed |
| EP-2015770-A2 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-01-21 | — | — | EP | claimed |
| WO-2007128817-A2 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | claimed |
| CN-107412742-B | Pharmaceutical composition comprising a GLP-1 peptide or exendin-4 peptide and a basal insulin peptide | 诺沃—诺迪斯克有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-101437849-B | insulin derivatives | NOVO NORDISK A/S (DK) | 2015-09-30 | — | — | CN | disclosed |
| EP-2386572-B1 | Insulin derivative | NOVO NORDISK AS (DK) | 2015-07-08 | — | — | EP | disclosed |
| US-8937042-B2 | Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide | NOVO NORDISK A/S (DK) | 2015-01-20 | — | — | US | disclosed |
| US-8933021-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| EP-2670773-A1 | PURIFICATION OF INSULIN | Novo Nordisk A/S (DK) | 2013-12-11 | — | — | EP | disclosed |
| EP-2209800-B1 | STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING LIRAGLUTIDE AND DEGLUDEC | NOVO NORDISK AS (DK) | 2013-07-24 | — | — | EP | disclosed |
| EP-2597103-A1 | Pharmaceutical compositions containing insulin and an insulinotropic peptide | NOVO NORDISK A/S (DK) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012104339-A1 | PURIFICATION OF INSULIN | NOVO NORDISK A/S (DK) | 2012-08-09 | — | — | WO | disclosed |
| EP-2386572-A1 | Insulin derivative | Novo Nordisk A/S (DK) | 2011-11-16 | — | — | EP | disclosed |
| US-8039101-B2 | Radio-opaque dental prosthetic member | Societe de Recherches Techniques Dentaires-R.T.D. (FR) | 2011-10-18 | — | — | US | disclosed |
| US-20110152185-A1 | Pharmaceutical Compositions Comprising GLP-1 Peptides or Extendin-4 and a Basal Insulin Peptide | NOVO NORDISK A/S (DK) | 2011-06-23 | — | — | US | disclosed |
| EP-2209800-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLP-1 PEPTIDES OR EXENDIN-4 AND A BASAL INSULIN PEPTIDE | Novo Nordisk A/S (DK) | 2010-07-28 | — | — | EP | disclosed |
| US-20090239785-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| WO-2009063072-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN AND AN INSULINOTROPIC PEPTIDE | NOVO NORDISK A/S (DK) | 2009-05-22 | — | — | WO | disclosed |
| EP-2015770-A2 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007128817-A2 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239785-A1 | Insulin Derivative | IAPP, INSR, GPR119 | TP53 4041/4885TSHR 1025/4885PLA2G4B 2981/4885 |
| US-20110152185-A1 | Pharmaceutical Compositions Comprising GLP-1 Peptides or Extendin-4 and a Basal Insulin Peptide | IAPP, GLP1R, GCG | TP53 3814/4885TSHR 953/4885PLA2G4B 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.